Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Wilson Bautista-Molano¹, Ingrid Ramirez-bolivar², Cristina Pinilla-Forero³ and Luz A Ruiz⁴, ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²Janssen, Bogotá, Colombia, ³Janssen, Bogotá, ⁴CODENTMED, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…
Abstract Number: 2316 • ACR Convergence 2024
Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
Pauline KRUG¹, angela De Sousa Leite², Frédéric Lecouvet¹, Maria Simona stoenoiu¹ and Adrien Nzeusseu Toukap³, ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires St-Luc, Brussels, Belgium, ³Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a highly heterogenous chronic inflammatory condition. Recent publications highlight differences between men and women in disease manifestation and response to…
Abstract Number: 2333 • ACR Convergence 2024
Unveiling New Molecular Signatures in Psoriatic Arthritis Using Comprehensive Proteomic Analysis of Peripheral Mononuclear Cells
Eduardo Martin-Salazar¹, Iván Arias-de la Rosa², Laura Cuesta-López³, María Lourdes Ladehesa-Pineda⁴, Miriam Ruiz-Ponce³, Antonio Barranco³, Maria Angeles Puche-Larrubia⁵, Carlos Perez-Sanchez³, Yas Hanaee³, Pedro Ortiz-Buitrago³, Rosario Lopez Pedrera³, Alejandro Escudero-Contreras³, Eduardo Collantes-Estevez⁶, Clementina López Medina⁷ and Nuria Barbarroja³, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordonba, Spain, ²Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁵Reina Sofía University Hospital, Cordoba, Spain, ⁶Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba 14012, Spain, ⁷Reina Sofia University Hospital, Cordoba, Spain
Background/Purpose: Diagnosing psoriatic arthritis (PsA) is challenging, underscoring the importance of discovering novel biomarkers through proteomics for early and accurate detection. Molecular clustering can elucidate…
Abstract Number: 2354 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
Alan Kivitz¹, Liliana Sedova², Melvin Churchill³, Cynthia Vizcaya⁴, Reema Sutariya⁵, Wenhao Cao⁵ and Atul Singhal⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institute of Rheumatology, Prague, and Clinic of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Southwest Arthritis Research Group, Mesquite, TX
Background/Purpose: To assess baseline demographics and clinical characteristics of patients with PsA that are most associated with achievement of clinical response to intravenous (IV) secukinumab…
Abstract Number: 2586 • ACR Convergence 2024
Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
Maria Gabriella Raimondo¹, Hashem Mohammadian², Stefano Alivernini³, Simon Rauber¹, Filippo Fagni⁴, Giulia Corte⁵, Koray Tascilar², Maria Antonietta D´Agostino⁶, Georg Schett⁷, Arnd Kleyer⁸ and Andreas Ramming¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, Rome, Italy, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ⁶Catholic University of Sacred Heart, Rome, Italy, Rome, Italy, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Charité - Universittsmedizin Berlin, Erlangen, Germany
Background/Purpose: Enthesitis is considered to be an early event in psoriatic arthritis (PsA) course, representing a hallmark feature of the disease. So far, most of…
Abstract Number: 0067 • ACR Convergence 2024
Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells
Shashank Cheemalavagu, Unnikrishnan Chandrasekharan, Oliver Wessely, Uyen Tran and M. Elaine Husni, Cleveland Clinic, Cleveland, OH
Background/Purpose: Early diagnosis of Psoriatic Arthritis (PsA) is critical for timely intervention to prevent poor clinical outcomes. Despite well-known clinical predictors of PsA, the mechanisms…
Abstract Number: 0231 • ACR Convergence 2024
Imaging Characteristics and Demographic Variations in Patients with Axial Spondylarthritis, Axial Psoriatic Arthritis, and Inflammatory Bowel Disease-Related Arthritis with Axial Involvement: Insights from a Single Center at Cleveland Clinic Abu Dhabi
Rajaie Namas¹, Ahlam Almarzooqi², Sarah Al Qassimi³ and Esat Memisoglu³, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Emirates Health Services, Sharjah, United Arab Emirates, ³Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Background/Purpose: Spondyloarthropathies (SpAs) are a group of seronegative, inflammatory arthritides, including axial spondylarthritis (ax-SpA), axial psoriatic arthritis (ax-PsA), and inflammatory bowel disease related arthritis with…
Abstract Number: 0589 • ACR Convergence 2024
Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
Laura Coates¹, Iain McInnes², M. Elaine Husni³, Cynthia Vizcaya⁴, Weibin Bao⁵ and Philip Mease⁶, ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ³Cleveland Clinic, Cleveland, OH, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease that can manifest with considerable clinical heterogeneity. Secukinumab demonstrated improvements across the updated Group for Research and…
Abstract Number: 1006 • ACR Convergence 2024
Associations Between Rheumatic Diseases and Mental Health Disorders
Thoai Vu, Sivam Bhatt and Janet Lewis, University of Virginia, Charlottesville, VA
Background/Purpose: Rheumatic diseases are frequently linked to a reduced quality of life (QoL), particularly as disease severity escalates. Patients with rheumatic conditions often exhibit high…
Abstract Number: 1389 • ACR Convergence 2024
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Amy Peeters¹, Maike Wientjes², Wieland Müskens¹, David Ten Cate³, Bart van den Bemt⁴, Noortje van Herwaarden¹ and Alfons den Broeder², ¹Sint maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Sint Maartenskliniek, Rotterdam, Netherlands, ⁴Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Since the compound patent on the bio-originator of adalimumab expired, several adalimumab biosimilars (BS) have been introduced. Extensive research shows equivalence in effectiveness and…
Abstract Number: 1469 • ACR Convergence 2024
Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain
María Rocío González Molina¹, C Marín Huertas², B Joven-Ibáñez³, L de Prado⁴, Lourdes Mateo⁵, M Llanes Gómez⁶, A Hernández del Río⁷, EA Blanco-Morales⁸, J Malavé Calzada⁹, Meritxell Sallés Lizarzaburu¹⁰, Inmaculada Ros-Vilamajó¹¹, Martina Steiner¹², EVELIN CERVANTES PEREZ¹³, Vanesa Hernández-Hernández¹⁴, S Castro Oreiro¹⁵, ANA URRUTICOECHEA¹⁶, L Orpinell Palacio¹⁷, J Campos Esteban¹⁸, Raúl Veroz González¹⁹, O Camacho Alcázar²⁰, MP Moreno-Gil²¹, A Aragón Díez²², MJ Moreno-Ramos²³, FJ Maceiras Pan²⁴, S Díaz-Castroverde²⁵, Santiago Muñoz Fernández²⁶, JA Pinto Tasende²⁷ and J Ramírez García²⁸, ¹Hospital Reina Sofía, Murcia, Murcia, Spain, ²Hospital Infanta Leonor, Madrid, Madrid, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ⁴Hospital de Mollet, Mollet del Vallès, Barcelona, Catalonia, Spain, ⁵H Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital Juan Ramón Jiménez, Huelva, Andalucia, Spain, ⁷Hospital Naval, Ferrol, A Coruña, Galicia, Spain, ⁸Hospital Virgen del Rocío, Sevilla, Andalucia, Spain, ⁹Hospital Virgen del Puerto, Plasencia, Cáceres, Extremadura, Spain, ¹⁰Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ¹¹Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ¹²Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, ¹³Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ¹⁴Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, ¹⁵Hospital Sant Joan XXIII, Tarragona, Catalonia, Spain, ¹⁶Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain, ¹⁷Hospital Sagrat Cor, Barcelona, Spain, ¹⁸Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁹Hospital Mérida, Badajoz, Spain, ²⁰Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Catalonia, Spain, ²¹Hospital San Pedro de Alcántara, Cáceres, Extremadura, Spain, ²²Hospital Universitario de Getafe, Getafe, Madrid, Madrid, Spain, ²³Hospital Virgen de Arrixaca, Murcia, Murcia, Spain, ²⁴Hospital de Meixoeiro, Pontevedra, Galicia, Spain, ²⁵Johnson&Johnson Innovative Medicine, Madrid, Madrid, Spain, ²⁶Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain, ²⁷Complejo Hospitalario Universitario, A Coruña, Spain, ²⁸Hospital Clínic, Barcelona, Spain
Background/Purpose: PsA is a complex inflammatory condition affecting both the skin and musculoskeletal system. Clinical guidelines recommend biological therapies after conventional synthetic DMARDs (csDMARDs) inadequate…
Abstract Number: 1912 • ACR Convergence 2024
Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Cassie Clinton⁵, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: There is regional variation in the clinical characteristics, treatment, and outcomes of patients with inflammatory arthritis in the US. Despite a higher reported prevalence of…
Abstract Number: 2317 • ACR Convergence 2024
Chronic Kidney Disease in Patients with Psoriatic Arthritis: A Cohort Study
Fadi Kharouf¹, Shangyi Gao², Shahad Al-Matar³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Chronic kidney disease (CKD) is a comorbidity in psoriatic arthritis (PsA). In this study, we aimed to define the prevalence of CKD in patients…
Abstract Number: 2334 • ACR Convergence 2024
Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)
Murat Torgutalp¹, Valderilio Azevedo², Xenofon Baraliakos³, Filip Van den Bosch⁴, Jürgen Braun⁵, Alberto Cauli⁶, Laura Coates⁷, Vinod Chandran⁸, Torsten Diekhoff⁹, Floris van Gaalen¹⁰, Rodrigo Garcia Salinas¹¹, Lianne S Gensler¹², Niti Goel¹³, Alice Gottlieb¹⁴, Desiree van der Heijde¹⁵, Philip Helliwell¹⁶, Kay Geert Hermann¹⁷, Umut Kalyoncu¹⁸, Uta Kiltz¹⁹, Robert Lambert²⁰, Ying Ying Leung²¹, Maria Llop²², Alejandra Lopez²³, Miranda van Lunteren²⁴, Ajesh Maharaj²⁵, Walter Maksymowych²⁶, Helena Marzo-Ortega²⁷, Ashish J Mathew²⁸, Philip Mease²⁹, Peter Nash³⁰, Mikkel Ostergaard³¹, Fabian Proft³², Mikhail Protopopov³³, Sherry Rohekar³⁴, RUXANDRA ELENA SCHIOTIS³⁵, Joachim Sieper³⁶, Enrique R. Soriano³⁷, Lai-shan Tam³⁸, James Wei³⁹, Nelly Ziade⁴⁰, Dafna Gladman⁴¹ and Denis Poddubnyy⁴², and AXIS Cohort Investigators, ¹Charite Universitatsmedizin - Berlin, Berlin, Germany, ²Department of Internal Medicine, Universidade Federal of Paraná, Curitiba, Brazil, Curitiba, Brazil, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Ghent University Hospital, Ghent, Belgium, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany., Herne, Germany, ⁶University of Cagliari, Cagliari, Italy, ⁷University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁸University of Toronto, Toronto, ON, Canada, ⁹Charite Universitatsmedizin Berlin, Berlin, Germany, ¹⁰LUMC, Leiden, Zuid-Holland, Netherlands, ¹¹Hospital Italiano La Plata, La Plata, Argentina, ¹²Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Caduceus Biomedical Consulting, Duke University, Durham, NC, ¹⁴Department of Dermatology, Icahn School of Medicine, New York, NY, USA., New York, NY, ¹⁵Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Leeds, United Kingdom, ¹⁷Charite Medical School, Berlin, Germany, ¹⁸Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ²⁰University of Alberta, Edmonton, AB, Canada, ²¹Singapore General Hospital, Singapore, Singapore, ²²Hospital Parc Tauli, Sabadell, Spain, ²³Centro Dermatológico del Country, Guadalajara, Jalisco, Mexico, Guadalajara, Mexico, ²⁴Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²⁵Department of Internal Medicine & Therapeutics, Faculty of Health Sciences. Walter Sisulu University, Eastern Cape, South Africa, Eastern Cape, South Africa, ²⁶Department of Medicine, University of Alberta, Edmonton, AB, Canada; CARE Arthritis, Edmonton, AB, Canada, Edmonton, Canada, ²⁷NIHR Leeds BRC, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Leeds, United Kingdom, ²⁸Christian Medical College, Vellore, Tamil Nadu, India, ²⁹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³⁰School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, ³¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³³Charite – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³⁴Western University, London, Ontario, Canada, London, Canada, ³⁵SPITAL CLINIC DE BOLI INFECTIOASE CLUJ NAPOCA, Cluj-Napoca, Romania, ³⁶Charité University Medicine Berlin, Berlin, Germany, ³⁷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³⁸The Chinese University of Hong Kong, New Territories, Hong Kong, ³⁹Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China), ⁴⁰Saint-Joseph University, Beirut, Lebanon, ⁴¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴²Charite-Universitatsmedizin Berlin, Berlin, Germany
Background/Purpose: Axial involvement, affecting the sacroiliac joints (SIJ) and/or spine, is a clinically relevant manifestation of psoriatic arthritis (PsA) that can influence management strategies. Previous…
Abstract Number: 2355 • ACR Convergence 2024
Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials
Laure Gossec¹, Andra Balanescu², Maria Antonietta D'Agostino³, Alexis Ogdie⁴, Philipp Sewerin⁵, Yu Deng⁶, Linyu Shi⁶, Yoshiyuki Sugimoto⁷, Sheng Zhong⁶, Yunzhao Xing⁶, Ralph Lippe⁶ and Mitsumasa Kishimoto⁸, ¹Sorbonne Université, Paris, France, ²UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ³Versailles-Saint-Quentin University (INSERM U1173, Laboratoire d’Excellence INFLAMEX); University Hospital Ambroise Paré, Versailles, France, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Bochum, Germany, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie GK, Tokyo, Tokyo, Japan, ⁸Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Risankizumab (RZB), an IL-23 p19 inhibitor, is well tolerated and provides long-term efficacy through 100 weeks in adults with PsA, demonstrated by the phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].